RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - Final results from the phase II ICLL03 RICAC-PMM trial (FILO - SFGM-TC French intergroup)

Introduction: Reduced intensity conditioning (RIC) allogeneic stem cell transplantation (ASCT) remains a potentially curative strategy in high-risk CLL. Post-ASCT relapse can be predicted by positive minimal residual disease (MRD) at 12m. We present the final results of a prospective trial on the efficacy and safety of a post-ASCT preemptive immunointervention (PrIm) based on serial MRD assessment in high-risk CLL (NCT01849939).